Clínic Barcelona

Researchers discover new applications of the drug fingolimod to improve cognitive deficits in Huntington’s disease

Fingolimod, a drug used to treat multiple sclerosis, restores hippocampal synaptic plasticity and improves memory function. This is the main conclusion of a study developed by researchers at the University of Barcelona (UB) and the IDIBAPS in a mouse model of Huntington disease (HD). The study has been published in the journal Human Molecular Genetics and highlighted by the journal Nature Reviews Neurology. The study is led by Dr. Jordi Alberch head of the Consolidated Research Group on Pathophysiology of Neurodegenerative Diseases of the UB and researcher at IDIBAPS. The first author is Dr. Andrés Míguez, researcher in Dr. Alberch’s group hired through the BIOTRACK Programme, an IDIBAPS project to incorporate postdoctoral researchers funded by the European Commission through the Marie Curie Actions (COFUND category).